These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Biochemical bone markers in the assessment and pamidronate treatment of children and adolescents with osteogenesis imperfecta. Aström E; Magnusson P; Eksborg S; Söderhäll S Acta Paediatr; 2010 Dec; 99(12):1834-40. PubMed ID: 20726960 [TBL] [Abstract][Full Text] [Related]
4. [A query from medical practice: the biological half-life of biphosphonates]. Bartl R Dtsch Med Wochenschr; 2008 Dec; 133(51-52):2700-1. PubMed ID: 19067274 [No Abstract] [Full Text] [Related]
5. Hearing in bisphosphonate-treated children with osteogenesis imperfecta: our experience in thirty six young patients. Ting TH; Zacharin MR Clin Otolaryngol; 2012 Jun; 37(3):229-33. PubMed ID: 22708940 [No Abstract] [Full Text] [Related]
6. [Bisphosphonate treatment of children and adolescents]. Illum NO Ugeskr Laeger; 2003 Jan; 165(5):454-6. PubMed ID: 12599842 [No Abstract] [Full Text] [Related]
7. Bisphosphonate treatment of children and adults with osteogenesis imperfecta: unanswered questions. Brizola E; Shapiro JR Calcif Tissue Int; 2015 Aug; 97(2):101-3. PubMed ID: 26071113 [TBL] [Abstract][Full Text] [Related]
8. Alendronate treatment in children with osteogenesis imperfecta. Akcay T; Turan S; Guran T; Bereket A Indian Pediatr; 2008 Feb; 45(2):105-9. PubMed ID: 18310788 [TBL] [Abstract][Full Text] [Related]
9. Bisphosphonates, osteonecrosis, osteogenesis imperfecta and dental extractions: a case series. Schwartz S; Joseph C; Iera D; Vu DD J Can Dent Assoc; 2008; 74(6):537-42. PubMed ID: 18644240 [TBL] [Abstract][Full Text] [Related]
10. Reduction of plasma taurine level in children affected by osteogenesis imperfecta during bisphosphonate therapy. D'Eufemia P; Finocchiaro R; Zambrano A; Tetti M; Ferrucci V; Celli M Biomed Pharmacother; 2007 May; 61(4):235-40. PubMed ID: 17275249 [TBL] [Abstract][Full Text] [Related]
15. Decrease of serum alkaline phosphatase after three cycles of pamidronate disodium in children with severe osteogenesis imperfecta. Cabral de Menezes Filho H; Rodrigues JM; Radonsky V; Della Manna T; Kuperman H; Steinmetz L; Dichtchekenian V; Damiani D; Setian N Horm Res; 2007; 68 Suppl 5():207-8. PubMed ID: 18174750 [No Abstract] [Full Text] [Related]
16. Pulmonary function tests in an infant with osteogenesis imperfecta and early biphosphonate treatment. Rugolotto S; Monti E; Carli M; Pietrobelli A; Antoniazzi F; Tato L Acta Paediatr; 2007 Dec; 96(12):1856-7. PubMed ID: 18001342 [No Abstract] [Full Text] [Related]
18. Uncomplicated vaginal delivery in two consecutive pregnancies carried to term in a woman with osteogenesis imperfecta type I and bisphosphonate treatment before conception. Chen CP; Lin SP; Su YN; Huang JP; Chern SR; Su JW; Wang W Taiwan J Obstet Gynecol; 2012 Jun; 51(2):305-7. PubMed ID: 22795118 [No Abstract] [Full Text] [Related]
19. Effect of intravenous pamidronate therapy on everyday activities in children with osteogenesis imperfecta. Löwing K; Aström E; Oscarsson KA; Söderhäll S; Eliasson AC Acta Paediatr; 2007 Aug; 96(8):1180-3. PubMed ID: 17578486 [TBL] [Abstract][Full Text] [Related]